To use all functions of this page, please activate cookies in your browser.
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
Amylon Therapeutics wins Startup Slam Competition at BIO-Europe® BerlinStartup Slam sponsor Johnson & Johnson Innovation recognise high calibre of diverse European entries
Amylon Therapeutics was today announced as the winner of the Startup Slam competition at this year’s BIO-Europe® 2017 annual conference in Berlin. Thomas de Vlaam, CEO and founder of Amylon Therapeutics, will receive a complimentary registration to BIO-Europe® Spring 2018 from EBD Group and the opportunity to enter a year-long no fee arrangement to become a Johnson & Johnson Innovation, JLINX community member.
Eight international startups from the life sciences sector pitched at this special session, sponsored by Johnson & Johnson Innovation for the fourth year running. All contestants had to present their company and innovation—either a new therapeutic product or medical technology platform—in only three minutes to a floor of experienced investors and potential collaboration partners.
Amylon Therapeutics targets Central Nervous System (CNS) disorders through an ultra-genetics approach, focusing on rare genetic disorders that can serve as a possible gateway to more frequently occurring indications.
Judge Regina Hodits, from Wellington Partners said, “The pitches from all eight finalists were extremely impressive, which made the job of selecting one winner very difficult for me and my fellow judges. We heard from startups involved in cutting-edge research, including using artificial intelligence to treat neurological disorders, developing pioneering products for skin lesions with exosomes secreted from umbilical cord blood cells and cultivating healthy gut bacteria for personalised microbiome therapies. However, Amylon therapeutics stood out because of the potential of their innovation to translate into transformative healthcare solutions for patients.”
Tom Aelbrecht, Head of the Janssen Campus Office (JCO) and Johnson & Johnson Innovation, JLINX in Beerse, Belgium, added, “Congratulations to Thomas de Vlaam and we are excited to invite Amylon Therapeutics to be part of the JLINX community. This well-established session provides an exclusive platform for high calibre entrepreneurs to pitch their innovation to a room of influencers and investors who can help advance the most promising science.”
- BRAIN AG announces strategic collaboration with BluCon Biotech GmbH
- Galapagos and MorphoSys announce start of a Phase 1 subcutaneous bridging study with MOR106
- EMBL Ventures Portfolio Company, ViraTherapeutics Acquired by Boehringer Ingelheim in EUR 210 Million Transaction
- Cellular memory outwits pathogens
- WACKER Invests in Jena Biotech Site